Semaglutide
Ozempic, Rybelsus, Wegovy
A long-acting GLP-1 receptor agonist used for type 2 diabetes and obesity management by enhancing insulin secretion and suppressing appetite.
Completed
PHASE1
NCT05784402
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT02054897
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06634927
Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE4
NCT07275697
Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study
Emma Svennberg
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NCT06182618
Retrospective Analysis for Patients With Metabolic Syndrome
Second Affiliated Hospital, School of Medicine, Zhejiang University
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05040971
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT06500429
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Neurogastrx, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT06149260
Subcutaneous Semaglutide in Systemic Scleroderma
Second Xiangya Hospital of Central South University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04560998
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05669755
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT04083820
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
Novo Nordisk A/S
OBSERVATIONAL
Updated Dec 15, 2025
Completed
NCT06659679
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
Brigham and Women's Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Completed
NCT04469855
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
Novo Nordisk A/S
OBSERVATIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT07163624
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
The United Bio-Technology (Hengqin) Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT02231684
Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE3
NCT07139548
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
Guangdong Raynovent Biotech Co., Ltd
INTERVENTIONAL
Updated Dec 15, 2025
Enrolling By Invitation
PHASE4
NCT06959784
Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
China-Japan Friendship Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT02254291
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE3
NCT06788626
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
Wei Hu
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05751226
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
Boehringer Ingelheim
INTERVENTIONAL
Updated Dec 15, 2025